Abstract: Thrombolytic drugs are used in medicine to dissolve blood clots in a procedure termed thrombolysis. To prevent occlusion, patients are treated with an antiplatelet or antithrombotic drug, or a combination of both. However, the traditional thrombolytic therapies have often been associated with the risk of severe bleeding. We have incorporated low molecular weight heparin (LMWH) and/or streptokinase to biodegradable polyvinyl alcohol (PVA) and gelatine biomaterials in a form of films. These biomaterials will be used to decorate inner surfaces of experimental vascular grafts to evaluate the potential of enhancing their thromboresistance by controlled release of one or both the active compounds. Solvent casting method was used to produce the PVA and crosslinked gelatine films. High initial burst release of LMWH has been observed during our in vitro experiments, followed by a slow stable release during subsequent hours. Biomaterials with LMWH incorporated in the vascular graft luminal surface can be used to prevent thrombus formation shortly after the surgery graft implantation and decrease it in the following hours. Slow stable streptokinase release can be used to attenuate excessive fibrin deposition inside the graft.
Introduction
Thrombolytic drugs are used in medicine to dissolve blood clots in a procedure termed thrombolysis. To prevent occlusion, patients are treated with an antiplatelet or antithrombotic drug, or a combination of both. However, the traditional thrombolytic therapies have often been associated with the risk of severe bleeding. A performance improvement in small-diameter bypass grafts remains a clinical objective. Local application of antithrombotic agents in attenuating early fibrin deposition could favourably influence acute graft patency, and may improve long-term graft patency as well [1, 2] . A bioactive heparinised graft luminal surface has also been proved successful to improve graft patency in canine interposition models [3] .
We have incorporated low molecular weight heparin (LMWH) and/or streptokinase to biodegradable polyvinyl alcohol (PVA) and gelatine biomaterials in a form of films. These biomaterials will be used to decorate inner surfaces of experimental vascular grafts to evaluate the potential of enhancing their thromboresistance by controlled release of one or both the active compounds. Streptokinase creates an active complex which promotes the cleavage of the Arg/Val bond in plasminogen to form the proteolytic enzyme plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. LMWH belongs to the class of anticoagulant medications to prevent thrombus formation.
Material and methods

Materials
LWM heparin (LMWH) Fraxiparine Forte (Glaxo Wellcome Production, France) was an injection solution containing Nadroparin calcium 19,000 IU anti-Xa in 1 ml of the solution. Streptokinase is from β-hemolytic Streptococcus (Lancefield Group C), lyophilised powder ≥50,000 units/mg protein (Sigma-Aldrich, Czech Republic). S-2251 TM chromogenic substrate (Chromogenix, USA), PVA, average Mw 130,000 (Sigma-Aldrich, Czech Republic), and gelatine, from porcine skin, gelstrength 300, Type A (Sigma-Aldrich, Czech Republic) were used. Bovine serum albumin (BSA) as a lyophilised powder had ≥96% purity (Sigma-Aldrich, Czech Republic) Tween 60 (Sigma-Aldrich, Czech Republic), plasminogen from bovine plasma, lyophilised powder, ≥2 units/mg protein (Sigma-Aldrich, Czech Republic), and transglutaminase (TGA) Activa, powder (Ajinomoto, Japan) were used.
Preparation of PVA and gelatine films with streptokinase
Solvent casting method was used to produce the films. 0.5 ml of distilled water containing 25 kU of streptokinase was mixed with 0. ml of 7% (w/v) PVA solution in a small plastic Petri dish with 35 mm diameter. Alternatively, 0.5 ml of distilled water containing 25 kU of streptokinase was mixed with 0.5 ml of 10% (w/v) gelatine solution, pH was adjusted to 7.0, and 10 mg of transglutaminase was added. The Petri dishes were placed to a thermostat and the films were obtained by drying at 40°C.
Preparation of PVA films with LWMH
Solvent casting method was used to produce the films. 2 ml of the Fraxiparine Forte injection solution were always mixed with 2 ml of 7% (w/v) PVA solution in a small plastic Petri dish with 35 mm diameter. The Petri dishes were placed in a thermostat and the films were obtained by drying at 40°C. The dried films were taken out of the Petri dishes and used for the in vitro release tests before (control) and after thermal curing at 70°C or 120°C for 60 min.
Determination of the kinetics of LMWH and streptokinase release by in vitro test
Kinetics of LMWH and streptokinase release from the biomaterials have been determined in vitro. The dry films with LMWH were placed in 10 ml of distilled water to a shaker under slow shaking at 37°C. 200 µl samples of the solution were collected in given time intervals during the extraction. The dry films with streptokinase were extracted in 3 ml of 0.5 M Tris-HCl buffer, pH 7.4, under same conditions. The experiment was performed in triplicate.
Determination of streptokinase activity
Streptokinase activity is determined by comparing its capacity to activate plasminogen to form plasmin with reference streptokinase standard. Plasminogen activation is measured using the plasmin-specific substrate S-2251™. The rate of formation of hydrolytic product from the plasmin-specific substrate is measured at 405 nm and this photometric signal is directly proportional to the plasmin activity. One unit was defined as the amount of enzyme activity that converts 1 µmol of substrate per minute per litre.
The reaction was performed using 96-well plates. In the test wells the reaction was performed after addition of 50 µl extraction buffer solutions collected during in vitro release tests to 150 µl S-buffer and 50 µl R-solution (see the compositions of S-buffer and P solution bellow). The plate was immediately placed in the plate reader Sunrise (XFLUOR4 Version: V 4.51) previously heated at 37°C. The absorbance in the wells was measured at 405 nm every 60 min. Each sample was assayed a minimum of three times. Mean values of absorbance increments in the wells were compared with the reference standards to calculate the streptokinase activity in the samples. 
S-buffer composition
Determination of LMWH activity
GP-HPLC separations were conducted using Agilent Technologies 1200 Series chromatograf and Superdex 75 10/300 GL (300 × 10 mm) column (Amersham Biosciences AB). Isocratic elution was performed at 30°C with 0.1 M Na 2 HPO 4 as eluent at a flow rate of 0.5 ml.min -1 . A calibration curve was used for quantification of LMWH in the samples collected during the in vitro release experiments. Figure 1 shows cumulative release of LMWH from PVA film, before (control) and after thermal treatment at 70°C or 120°C. High initial burst release of more than 50% of LMWH in the first 30 min has been observed. This initial burst release was decreased significantly after thermal treatment at 70°C or 120°C. The initial burst decline was more profound after the thermal treatment at 70°C. The films were almost insoluble in water, because of the high molecular weight of PVA used to prepare them. The initial burst was followed by a slow stable release during at least subsequent 10 h. Several research studies have been published concerning in vitro studies of LMWH sustained release from polymeric nanoparticles or microparticles, mesoporous silica, or nanofibre scaffolds for tissue engineering. Very slow stable release, lasting usually many days, has been observed from polymeric nanoparticles or microparticles [4] [5] [6] 9] , and mesoporous silica carriers [7, 8] . Heparin release from an electrospun poly-L-lactide scaffold showed an initial burst within the first 24 h, followed by a further sustained release profile [10] .
Results and discussion
In the vascular grafts, faster kinetics of LMWH release, observed in our experiment, can be advantageous to prevent thrombus formation in the first critical days after implantation before endoendothelial fibrin layer formation. Figure 2 shows cumulative release of streptokinase from films prepared from PVA or crosslinked gelatine. Slow stable streptokinase release from PVA and gelatine films without any initial burst was observed. Similar kinetics of streptokinase release from PVA and gelatine films have been observed. The kinetics was nearly linear during 5 h of the experiment. This experiment was aimed only to show the ability and approximate rate of streptokinase release rather than determining real kinetics of the process. New experiments with the aim to determine an exact kinetics of streptokinase release are in progress.
There are research studies describing in vivo studies concerning streptokinase sustained delivery from chitosan nanoparticles [11] , liposomes [12] , and pH-responsive hydrogel [13] . Yagmurlu et al. [14] described utilisation of streptokinase loaded PHBV membrane for reduction of surgery-induced peritoneal adhesions. No in-vitro release profiles for streptokinase are available at present time.
Conclusions
High initial burst release of LMWH has been observed during our in vitro experiments, followed by a slow stable release during subsequent hours. The initial burst of heparin can be decreased significantly by thermal curing of the PVA films. Because of the high initial burst, these biomaterials with LMWH incorporated in the vascular graft luminal surface can be used to prevent thrombus formation shortly after the surgery graft implantation and decrease it in the following hours.
No initial burst has been observed during the in vitro release experiments with streptokinase. Slow stable streptokinase release can be used to attenuate excessive fibrin deposition inside the graft.
Studies are planned to verify the biological activity of LMWH after leaching out of the biomaterial by measurement of activated partial thromboplast in time and thrombin clotting. The potential of the biomaterials to improve long-term graft patency has to be still evaluated by in vivo experiments.
